Protective effects of erythropoietin in cardiac ischemia - From bench to bedside
Protective effects of erythropoietin in cardiac ischemia - From bench to bedside
复制标题
DOI：
10.1016/j.jacc.2006.08.031
复制
发表时间：
2006-12-05
影响因子：
24
通讯作者：
van Gilst, Wiek H.
中科院分区：
文献类型：
--
作者：
Lipsic, Erik;Schoemaker, Regien G.;van Gilst, Wiek H.
促红细胞生成素(EPO)是一种低氧诱导的激素，产生于肾脏，刺激骨髓中的造血。然而，最近的研究也表明EPO具有重要的非造血作用。在心血管系统中发现了一种功能性的EPO受体，包括内皮细胞和心肌细胞。在动物研究中，EPO在心脏缺血/再灌注期间的治疗已被证明可以限制心肌梗死范围和细胞凋亡的程度。从长远来看，EPO可能通过刺激原位内皮细胞或动员骨髓内皮祖细胞来促进缺血诱导的新生血管形成。EPO在缺血心脏中的作用支持EPO作为一种多效性的组织保护剂的概念，以保护表达EPO受体的其他器官。我们最近进行了第一项随机临床研究，显示EPO在急性心肌梗死患者中应用的安全性和可行性。未来的临床研究有必要将EPO的有益作用从基础实验转化为心脏病患者。
Erythropoietin (EPO) is a hypoxia-induced hormone produced in the kidneys that stimulates hematopoiesis in the bone marrow. However, recent studies have also shown important nonhematopoietic effects of EPO. A functional EPO receptor is found in the cardiovascular system, including endothelial cells and cardiomyocytes. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis. In the longer term, EPO may promote ischemia-induced neovascularization, either by stimulating endothelial cells in situ or by mobilizing endothelial progenitor cells from bone marrow. The effects of EPO in the ischemic heart support the concept of EPO as a pleiotropic, tissue-protective agent for other organs expressing the EPO receptor. We recently performed a first randomized clinical study showing the safety and feasibility of EPO administration in patients with acute myocardial infarction. Future clinical studies are warranted to translate the beneficial effects of EPO from basic experiments to cardiac patients.